title: Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines.
abstract: BACKGROUND
  Olanzapine is used for treatment of psychiatric conditions but causes substantial weight gain. This study assessed safety, efficacy, and changes in metabolic cytokines associated with olanzapine administration in patients with cachexia due to advanced cancer.
  
  
  METHODS
  Patients with cancer-related cachexia were treated with olanzapine (doses ranging from 2.5 to 20 mg daily by mouth). Patients also received anti-neoplastic treatments. Serum samples were collected at baseline and after weeks 1, 2, 4, and 8 for analysis of levels of leptin, growth hormone, ghrelin, and interleukin-6 (IL-6).
  
  
  RESULTS
  Of the 39 participants, 31 were evaluable for weight change (N = 6 excluded for new ascites; N = 2, incomplete body weight of data). Toxicities related to olanzapine were somnolence (n = 1), pancreatitis (n = 1), extrapyramidal symptoms (n = 1), and nausea/vomiting (n = 1) (all grade 2). The recommended dose of Olanzapine is 20 mg PO daily for cancer patients (same as FDA approved dose for psychiatric conditions). Samples from 29 patients were eligible for analysis of serum cytokine levels. Mean values of leptin, ghrelin, and growth hormone did not change on treatment, though IL-6 levels increased, perhaps due to tumor progression. There was no association between changes in cytokines and weight. The mean change in slope of weight loss before versus after therapy was 0.24 (95 % CI, -0.08, 0.56; p = 0.13) indicating a trend, albeit not reaching statistical significance, toward attenuation of weight loss.
  
  
  CONCLUSIONS
  Changes in metabolic cytokines and body weight did not correlate. Treatment with olanzapine had only a modest effect in altering the trajectory of weight loss.
authors: Department of Investigational Cancer Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 455, Houston, TX, 77030, USA, anaing@mdanderson.org.
authors: Aung
authors: A
authors: Naing
authors: Shalini
authors: S
authors: Dalal
authors: Maen
authors: M
authors: Abdelrahim
authors: Jennifer
authors: J
authors: Wheler
authors: Kenneth
authors: K
authors: Hess
authors: Siqing
authors: S
authors: Fu
authors: David S
authors: DS
authors: Hong
authors: Filip
authors: F
authors: Janku
authors: Gerald S
authors: GS
authors: Falchook
authors: Alyson
authors: A
authors: Ilustre
authors: Fengying
authors: F
authors: Ouyang
authors: Razelle
authors: R
authors: Kurzrock
mesh_terms: D000328:Adult; D000368:Aged; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects*; D002100:Cachexia / Q000097:blood* / Q000188:drug therapy*; D016207:Cytokines / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D005260:Female; D054439:Ghrelin / Q000097:blood; D006801:Humans; D015850:Interleukin-6; D020738:Leptin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000378:metabolism*; D000077152:Olanzapine; D015430:Weight Gain / Q000187:drug effects; D015431:Weight Loss / Q000187:drug effects
chemical_list: D016207:Cytokines; D054439:Ghrelin; D015850:Interleukin-6; D020738:Leptin; D001569:Benzodiazepines; D000077152:Olanzapine